No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - American pharmaceutical giant Pfizer expects revenues and profits to slip slightly in 2026, partly as a result of lost revenues from its Covid-19 products.
In an analyst and investor call on Tuesday, the company said it was revising its 2025 revenue guidance to $62.0bn, slightly below the mid-point of its previous guidance of $61bn-64bn. Earnings per share are tipped to come in at $3.00-3.15.
Current consensus forecasts are for revenues of $62.5bn and EPS of $3.13.
For 2026, Pfizer said revenues would be in the range of $59.5-62.5bn, the mid-point of which represents a $1bn decline from 2025.
Revenues from Covid-19 products are now expected to be $1.5bn lower than what was expected in 2025, while the company will be hit by $1.5bn from the loss of exclusivity (LOE) on certain products. Excluding both Covid-19 and LOE products, operational revenue growth is forecast to be around 4% in 2026.
As for profits, the company pointed to 2026 EPS of $2.80-3.00.
"2025 was a year of strong execution and strategic progress for Pfizer," said chief executive Albert Bourla.
"We've strengthened our foundation, advanced our R&D pipeline and positioned our company for sustainable growth in the post-LOE period. As we move into 2026, we're focused on serving patients with innovative medicines and vaccines while creating long-term value for our shareholders."
Pfizer's stock was down 3.2% at $25.59 by 1512 GMT.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.